Bingxia Su

562 total citations
9 papers, 472 citations indexed

About

Bingxia Su is a scholar working on Biomaterials, Molecular Biology and Surgery. According to data from OpenAlex, Bingxia Su has authored 9 papers receiving a total of 472 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Biomaterials, 4 papers in Molecular Biology and 1 paper in Surgery. Recurrent topics in Bingxia Su's work include Nanoparticle-Based Drug Delivery (4 papers), Supramolecular Self-Assembly in Materials (2 papers) and Adenosine and Purinergic Signaling (1 paper). Bingxia Su is often cited by papers focused on Nanoparticle-Based Drug Delivery (4 papers), Supramolecular Self-Assembly in Materials (2 papers) and Adenosine and Purinergic Signaling (1 paper). Bingxia Su collaborates with scholars based in China, South Korea and United States. Bingxia Su's co-authors include Weiyue Lu, Changyou Zhan, Xiaoli Wei, Huitong Ruan, Zhilan Chai, Xuefeng Hu, Cao Xie, Danni Ran, Kuan Jiang and Linwei Lu and has published in prestigious journals such as Journal of Hazardous Materials, Journal of Controlled Release and Small.

In The Last Decade

Bingxia Su

9 papers receiving 471 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bingxia Su China 8 259 199 179 42 39 9 472
Anna Galstyan United States 10 202 0.8× 251 1.3× 235 1.3× 43 1.0× 44 1.1× 12 557
Rick Dorland Netherlands 5 209 0.8× 192 1.0× 94 0.5× 42 1.0× 35 0.9× 5 394
L. Yakovleva Russia 11 207 0.8× 261 1.3× 233 1.3× 19 0.5× 46 1.2× 24 540
Diana M. Leite United Kingdom 9 170 0.7× 141 0.7× 114 0.6× 45 1.1× 60 1.5× 13 370
Junning Ma United States 9 176 0.7× 164 0.8× 201 1.1× 37 0.9× 39 1.0× 9 398
Amanda Maffa United States 2 221 0.9× 140 0.7× 146 0.8× 40 1.0× 57 1.5× 2 383
Xiaoning Lin China 11 357 1.4× 187 0.9× 183 1.0× 109 2.6× 52 1.3× 27 713
Elena Balkanska-Sinclair United States 2 184 0.7× 140 0.7× 143 0.8× 38 0.9× 54 1.4× 3 339
Jason Lajoie United States 7 197 0.8× 123 0.6× 226 1.3× 63 1.5× 20 0.5× 10 553
Yaroslav Marchenko Russia 10 168 0.6× 268 1.3× 247 1.4× 25 0.6× 45 1.2× 25 486

Countries citing papers authored by Bingxia Su

Since Specialization
Citations

This map shows the geographic impact of Bingxia Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bingxia Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bingxia Su more than expected).

Fields of papers citing papers by Bingxia Su

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bingxia Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bingxia Su. The network helps show where Bingxia Su may publish in the future.

Co-authorship network of co-authors of Bingxia Su

This figure shows the co-authorship network connecting the top 25 collaborators of Bingxia Su. A scholar is included among the top collaborators of Bingxia Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bingxia Su. Bingxia Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Ruan, Huitong, Zhilan Chai, Qing Shen, et al.. (2018). A novel peptide ligand RAP12 of LRP1 for glioma targeted drug delivery. Journal of Controlled Release. 279. 306–315. 67 indexed citations
2.
Su, Bingxia, Ruifeng Wang, Zuoxu Xie, et al.. (2018). Effect of Retro‐Inverso Isomer of Bradykinin on Size‐Dependent Penetration of Blood–Brain Tumor Barrier. Small. 14(7). 24 indexed citations
3.
Chai, Zhilan, Xuefeng Hu, Xiaoli Wei, et al.. (2017). A facile approach to functionalizing cell membrane-coated nanoparticles with neurotoxin-derived peptide for brain-targeted drug delivery. Journal of Controlled Release. 264. 102–111. 215 indexed citations
4.
Liu, Min, Xue Li, Zuoxu Xie, et al.. (2016). D‐Peptides as Recognition Molecules and Therapeutic Agents. The Chemical Record. 16(4). 1772–1786. 56 indexed citations
5.
Xie, Zuoxu, Qing Shen, Cao Xie, et al.. (2015). Retro-inverso bradykinin opens the door of blood–brain tumor barrier for nanocarriers in glioma treatment. Cancer Letters. 369(1). 144–151. 29 indexed citations
6.
Li, Xue, Zuoxu Xie, Cao Xie, et al.. (2015). D-SP5 Peptide-Modified Highly Branched Polyethylenimine for Gene Therapy of Gastric Adenocarcinoma. Bioconjugate Chemistry. 26(8). 1494–1503. 22 indexed citations
7.
Li, Xue, Qing Dong, Zhiqiang Yan, et al.. (2015). MPEG-DSPE polymeric micelle for translymphatic chemotherapy of lymph node metastasis. International Journal of Pharmaceutics. 487(1-2). 8–16. 17 indexed citations
8.
Ge, Huilin, Shu‐Shen Liu, Bingxia Su, & Li‐Tang Qin. (2014). Predicting synergistic toxicity of heavy metals and ionic liquids on photobacterium Q67. Journal of Hazardous Materials. 268. 77–83. 41 indexed citations
9.
Ge, Huilin, et al.. (2013). [Microplate luminometry for toxicity bioassay of chemicals on luciferase].. PubMed. 33(10). 2766–70. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026